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BACKGROUND: Biochemical failure (BF) after radiation therapy is defined on the basis of a rising prostate-specific antigen (PSA)
level (A1 failure) or any event that prompts the initiation of salvage androgen-deprivation therapy without PSA failure (A2). It was
hypothesized that A2 failure may have a different prognosis. METHODS: Data for 2799 eligible patients from Radiation Therapy On-
cology Group (RTOG) 9202 and RTOG 9413 were analyzed. BF was defined according to the 1997 American Society for Therapeutic
Radiology and Oncology consensus definition as A1 for PSA failure or as A2 for the start of salvage hormone therapy before 3 con-
secutive PSA rises. RESULTS: Rates of all-cause mortality (hazard ratio [HR], 1.7; 95% confidence interval [CI], 1.5-2.0; P< .0001) and
distant metastasis (DM; HR, 1.6; 95% CI, 1.3-2.0; P<.0001) were greater with A2 failure. The 5-year overall survival (OS) rates were
88.2% and 74.6% for A1 and A2, respectively (P< .0001), and the DM rates were 15.7% and 29.0%, respectively (P< .0001). The DM
rate was greater at 5 years for A2 patients with DM as the first sign of failure versus patients with other A2 failures (87.3% vs 11.7%,
P< .001), and this also correlated with worse OS at 5 years: 81.1% for A2 failure without DM and 52.8% with DM (P< .001). After the re-
moval of patients with DM, the difference between A1 and A2 BF persisted for OS (P5 .002) but not for DM (P5.16) CONCLUSIONS:
These results suggest that patients with rising PSA levels alone have less risk than those with A2 failures; although DM was the largest
contributor of adverse risk to A2 failure, it did not account for all excess risk in A2 failure. Cancer 2015;121:844-52. VC 2014 American
Cancer Society.
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INTRODUCTION
Because of the long natural history of prostate cancer, for many studies, the use of prostate-specific antigen (PSA) to define
biochemical failure (BF) has replaced the use of clinical failure. Because of the multiple different definitions of BF in use,
in 1997, the American Society for Therapeutic Radiology and Oncology (ASTRO) convened a panel that established a
consensus definition of PSA failure, and this definition was in use for 10 years.1 This consensus definition initially
described failure as 3 consecutive rises in posttreatment PSA after the achievement of a nadir, with the date of failure
recorded as the time midway between the nadir and the first rising PSA level (ASTRO1 or A1). Subsequently, a second
type of failure, defined as the initiation of salvage androgen-deprivation therapy (ADT) for any reason other than 3 con-
secutive rises (ASTRO2 or A2), was added to capture what would otherwise be nonevaluable patients. A second ASTRO
consensus conference subsequently described a new “phoenix” definition for BF and amended the original PSA-based def-
inition (A1) to a rise of 2 ng/mL or more above the nadir PSA level, with the date of failure at call.2 In addition, the docu-
mentation of local or distant failure or the initiation of salvage ADT before the nadir1 2 ng/mL value was also included
in the phoenix definition (A2). However, the prognostic significance of failure as indicated by salvage ADT without an
express cutoff for rising PSA being met, whether it is based on the old or new ASTRO definitions, has not been well
explored.
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METHODS AND MATERIALS
Patients, Treatment, and Follow-Up
As part of an institutional review board approved second-
ary analysis data from 2799 eligible patients from Radia-
tion Therapy Oncology Group (RTOG) 9202 and
RTOG 9413 were analyzed. The details regarding
patient selection and treatment have been described pre-
viously.3,4 In RTOG 9202, patients had locally advanced
prostate cancer (T2c-T4) and pretreatment PSA lev-
els< 150 ng/mL. All patients received external-beam
radiation therapy (RT) to the whole pelvis, and this was
followed by a boost to the prostate to a total dose of 67.5
to 70 Gy. Patients were randomly assigned to receive
short-term ADT for 4 months starting 2 months before
RT or to the same regimen with an additional 2 years of
ADT (long-term ADT). In RTOG 9413, patients had
localized prostate cancer with a presumed risk of lymph
node involvement 15% on the basis of the Roach for-
mula.5 Patients were randomized into 4 groups accord-
ing to whether they started to receive short-term ADT
before or after RT and whether the prostate only or the
whole pelvis was treated.
Follow-up was scheduled every 3 to 4 months dur-
ing years 1 and 2, every 6 months during years 3 to 5, and
annually thereafter. During follow-up, any patient pre-
senting with bone pain not attributable to any intercur-
rent disease underwent a bone scan. The protocol did not
require a bone scan in asymptomatic patients with ele-
vated PSA levels.
Study Endpoints
BF according to the original ASTRO consensus defini-
tion was categorized into 1 of 2 types: 3 consecutive rises
in posttreatment PSA levels after the achievement of a
nadir (A1) or the initiation of salvage hormone therapy
for any reason other than A1 failure after the end of RT
(A2). A PSA rise was defined as a minimum of 0.2 ng/
mL at a minimum of 3 months after the end of RT. The
date of failure was defined as the halfway point between
the nadir date and the first rise for A1 and the start date
of salvage hormone therapy for any reason other than A1
(before the 3 consecutive rises) for A2. The PSA nadir
was defined as the lowest PSA level achieved after the
completion of RT. The time to BF was measured from
the randomization date to the date of failure. Overall sur-
vival (OS) was defined as death by any cause. Local fail-
ure was defined as tumor recurrence (positive rebiopsy at
least 2 years after study entry or tumor regrowth of 50%)
or a tumor never cleared by digital rectal examination.
Distant metastasis (DM) was defined as the documenta-
tion of clinical evidence of distant disease.
Statistical Methods
The chi-square test was used to compare pretreatment
characteristics, whereas the Kaplan-Meier method6 and
the log-rank test were used to estimate the rates for OS.7
The cumulative incidence method8 was used to estimate
the time to local failure and DM, with Gray’s test9 used to
compare the cumulative incidence rates over time between
treatment arms. For multivariate analyses, Cox propor-
tional hazard regression analysis10 was used for OS, and
Fine and Gray’s regression analysis11 was used for local
failure and DM. The proportional hazards assumptions
were assessed with both graphical approaches and
goodness-of-fit tests.12 The following categorical covari-
ates were considered for the combined data of RTOG
9202 and RTOG 9413: age (<70 [reference level] vs70
years), combined Gleason score (2-6 [reference level] vs 7-
10), PSA (30 [reference level] vs >30 ng/mL), clinical
stage (T2 [reference level] vs >T2), and study (RTOG
9202 [reference level] vs RTOG 9413). In addition to
these covariates, the PSA level at its nadir after RT (con-
tinuous), the time to the PSA nadir from randomization
(continuous), and the PSA change ([PSA at failure2PSA
at nadir]/[date of failure2 date of PSA nadir]; continu-
ous) were considered as covariates for each study and in
the combined data. All statistical comparisons were 2-
sided, and a P value< .05 was considered statistically sig-
nificant. SAS software (SAS Institute, Cary, NC) and R
software were used for all analyses.
RESULTS
Pretreatment Patient Characteristics
The median follow-up times were 9.0 and 6.5 years for
RTOG 9202 and RTOG 9413, respectively. The pre-
treatment characteristics for these studies have been pre-
viously described and are summarized in Table 1 for
patients with BF categorized as A1 or A2 failure. There
were no differences in age, PSA, T classification, Gleason
score, or lymph node status between those with A1 fail-
ure and those with A2 failure (all P> .05).
Type of BF
From both studies, there were 1181 BF events according
to the ASTRO consensus definition (663 of 1521 for
RTOG 9202 and 518 of 1278 for RTOG 9413). Overall,
42% of the patients experienced BF, and among the
patients who experienced BF, 56% (664 of 1181) were
diagnosed according to 3 rises in PSA (A1), whereas a
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substantial minority (44% [517 of 1181]) experienced A2
failure (47% [311 of 663] for RTOG 9202 and 40% [206
of 518] for RTOG 9413). Salvage ADTwas given to 34%
(951 of 2799) of all patients from the 2 studies (36% [553
of 1521] in RTOG 9202 and 31% [398 of 1278)] in
RTOG 9413); this rate was higher for patients with BF
defined as A2 (100% [517 of 517]) versus patients with
BF defined by rising PSA alone (A1; 65% [434 of 664]).
Survival Outcomes
At 5 years, the metastasis rate was greater for patients
with A2 failure versus those with A1 failure (29.0% vs
15.7%; hazard ratio [HR], 1.60; 95% confidence interval
[CI], 1.32-1.95; P< .0001; Fig. 1A). Among patients
with A2 failure, those with DM before or within 1 month
of the initiation of ADT had substantially greater DM at
5 years in comparison with those with all other A2 fail-
ures (87.3% vs 11.7%, P< .001; Fig. 1B and Table 2),
whereas there was no statistical difference in DM
between those with A1 failure and those with A2 failure
without initial DM (P5 .15). OS at 5 years was also
lower for those with A2 failure (88.2% vs 74.6%; HR,
1.68; 95% CI, 1.48-1.99; P< .0001; Fig. 1C), and this
again was worst for those with initial DM (52.8%) versus
those with other A2 failures (81.1%, P< .001; Fig. 1D).
However, A2 failure without initial DM was still associ-
ated with worse OS in comparison with A1 failure (5-
year rate: 88.2% vs 81.1%, P5 .0002). Local failure was
not different between BF types (19.6% vs 21.3%; HR,
1.01; 95% CI, 0.81-1.27; P5 .92) or by type of A2 fail-
ure. The impact of A2 failure was similar in RTOG 9413
and RTOG 9202 (Table 3).
Because of the heterogeneity identified in patients
with A2 failure, men with A2 failure were divided into 4
groups: those with a rising PSA level after RT without
decreasing PSA (pattern 1, n5 54); those who had an ini-
tially decreasing PSA level, achieved a PSA nadir, and sub-
sequently experienced an increase but did not meet the
definition for A1 failure (pattern 2, n5 284); those who
had irregular PSA patterns other than the previous 2 pat-
terns (pattern 3, n5 61); and finally those who had DM
as the first event or within 1 month of the initiation of
ADT (pattern 4, n5 118; Table 2). Those with DM as
the first sign of failure had the highest rate of DM at 5
years (pattern 4, 87.3%), and those with a rising PSA level
after the completion of RT also had a higher rate of DM
at 5 years (pattern 1, 37.3%) in comparison with those
with rising PSA levels who did not meet the definition of
A1 failure (pattern 2, 7.9%) and those with another PSA
pattern (pattern 3, 6.7%). The 5-year OS rate was also
worse for those with DM as the first sign of failure
(52.8%) and those with initially rising PSA after RT
(51.0%) in comparison with those with rising PSA
(90.3%) or another pattern (63.9%).
Stepwise multivariate regression models (Table 5)
identified an age 70 years (P< .00001), a Gleason score
of 7 to 10 (P< .0001), and A2 BF (P< .0001) as associ-
ated with an increased risk of all-cause mortality.
TABLE 1. Pretreatment Characteristics for RTOG 9202 and RTOG 9413 According to the ASTRO Definition
of Biochemical Failure
RTOG 9202 RTOG 9413
A1 (n5 352) A2 (n5 311) Total (n5 663) A1 (n5 312) A2 (n5 206) Total (n5 518)
Age, y
Median 69 69 69 69 69 69
Range 48-84 43-88 43-88 50-82 44-85 44-85
Prostate-specific antigen, ng/mL
Median 24.8 24.9 24.8 26.50 25.90 26.20
Range 0.20-250.00 0.123-228.40 0.123-250.00 2.00-92.50 2.85-98.20 2.00-98.20
Clinical stage, n (%)
T2 161 (46) 124 (40) 285 (43) 79 (25) 32 (15) 111 (21)
T3 177 (50) 167 (54) 344 (52) 35 (11) 16 (8) 51 (10)
T4 14 (4) 20 (6) 34 (5) 198 (63) 158 (77) 356 (69)
Gleason score, n (%)
<7 121 (34) 90 (29) 211 (32) 68 (22) 43 (21) 111 (21)
7-10 206 (59) 195 (63) 401 (60) 244 (78) 163 (79) 407 (49)
Missing 25 (7) 26 (8) 51 (8)
Nodal status, n (%)
Negative 109 (31) 90 (29) 199 (30) NA
Positive 22 (6) 23 (7) 45 (7)
Not done 221 (63) 198 (64) 419 (63)
Abbreviations: ASTRO, American Society for Therapeutic Radiology and Oncology; NA, not applicable; RTOG, Radiation Therapy Oncology Group.
Original Article
846 Cancer March 15, 2015
Similarly, a Gleason score of 7 to 10 (P5 .0012), a T clas-
sification>T2 (P< .0001), treatment in RTOG 9202
(P5 .00065), and A2 BF (P< .0001) all predicted higher
rates of metastasis. However, only a greater T classifica-
tion (P5 .0016) and treatment in RTOG 9202
(P5 .0024) predicted greater local failure, and neither the
Gleason score (P> .05) nor A2 BF (P5 .78) predicted
increased local failure.
PSA Kinetics in the Patients Who Failed by BF:
A1 Type
PSA-related variables—PSA nadir after RT, time to the
PSA nadir after RT, and rate of the PSA rise after its na-
dir—were each analyzed to assess their effects on the time
to BF for those with A1 BF (Table 4). The multivariate
analysis controlled for the following: age, PSA at the
baseline, T classification, Gleason score, and treatment
in RTOG 9202 or RTOG 9413. Among men who had
conventional BF due to rising PSA (as defined by A1), a
longer time to the PSA nadir in months (P< .00001;
HR, 0.99; 95% CI, 0.99-0.995) was associated with an
improved outcome, whereas a faster rate of the PSA rise
after its nadir (P< .0001; HR, 1.19; 95% CI, 1.12-1.27)
was associated with an earlier time to A1 BF. The PSA
nadir itself, however, was not a predictor of the time to
A1 BF across all patients or in the subset of patients
treated in RTOG 9202, but as previously documented,
the PSA nadir was prognostic for those treated in RTOG
9413 (data not shown).13,14
PSA Kinetics and Outcomes in Patients Who
Failed by BF: A2 Type
Finally, the influence of PSA kinetics was assessed inde-
pendently in those who had A2 BF (Table 2). The median
PSA at the time of A2 BF was higher for those with an ini-
tially rising PSA level after RT (pattern 1, 10.9 ng/mL)
Figure 1. (A) Freedom from distant metastasis (DM) as a function of A1 biochemical failure versus A2 biochemical failure. (B)
Freedom from DM as a function of A1 or A2 biochemical failure or initial DM. (C) Overall survival as a function of A1 biochemical
failure versus A2 biochemical failure. (D) Overall survival as a function of A1 or A2 biochemical failure or initial DM.
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and those with DM (pattern 4, 11.2 ng/mL) versus those
with patterns 2 and 3 (2.2 and 1.9 ng/mL, respectively).
In addition, the PSA doubling times were also shorter for
those with an initially rising PSA level (7.8 vs 22.6, 18.7,
and 11.4 months for patterns 2, 3, and 4, respectively).
Salvage Therapy
Finally, the use of salvage therapy could potentially have
influenced the clinical outcomes because all patients with
A2 failure by definition started ADT, whereas it might have
been delayed for those with A1 failure. The median time af-
ter BF to salvage ADT in all A1 failures was 23.8 months,
with 50.5% starting salvage ADT within the first 2 years af-
ter A1 BF. The rate of salvage ADT use did not differ when
it was based on the variables prognostic for outcomes in the
multivariate (MTV) analysis (Table 5), including the Glea-
son score (2-6 vs 7-10, P5 .32), T classification (T2 vs T3/
T4, P5 .54), and age (<70 vs 70 years, P5 .34),
although those treated in RTOG 9413 did have a shorter
median time to salvage ADT (21.4 vs 26.3 months in
RTOG 9202; HR, 1.40; 95%CI, 1.15-1.70; P5 .0007).
DISCUSSION
Prostate cancer patients treated in RTOG 9202 and
RTOG 9413 who were classified with BF due to the
initiation of salvage ADT for any reason other than the
study definition of PSA failure with 3 consecutive rises in
posttreatment PSA levels after the achievement of a nadir
appeared to have worse OS and DM rates than those who
had PSA rise–defined failure. The majority of this
increased risk was captured by those with DM as the first
sign of failure (Fig. 1C), although those with A2 failure
without initial DM did still have worse OS than those
with rising PSA alone (Fig. 1D). The corollary of this is
that BF documented by a rising PSA level alone (A1 fail-
ure), which occurred in 56% of the patients with BF, is
less risky than one might assume from an analysis of out-
comes for all patients with BF that does not account for
A1, A2, or DM as the first sign of failure. The apparent
lower risk with rising PSA alone as the cause of BF reinfor-
ces the growing concept that the early initiation of salvage
ADT may not provide clinical benefit.15 Nevertheless,
because salvage ADT use was very prevalent in these
patients after any BF, it is difficult to sort out the relative
clinical benefit of salvage ADT.
This is the first report of the significance of failure
according to the non–PSA rise definition, and failure was
observed across 2 different clinical trials with significantly
different ADT treatment schedules (4 vs 28 months). In
addition, this finding was seen in both univariate and
TABLE 3. Survival and Failure Rates at 5 Years According to the ASTRO Definition of Biochemical Failure
Endpoint
Biochemical
Failure
Patients,
n
Failure,
n
5-Year Failure/Survival
Rate,
% (95% CI)a HR (95% CI)b P
Combined data (n5 1181)
Overall survival A1 664 267 88.2 (85.7-90.7) RL
A2 517 299 74.6 (70.8-78.4) 1.68 (1.48-1.99) <.0001
Distant metastasis A1 664 193 15.7 (12.9-18.4) RL
A2 517 212 29.0 (25.1-33.0) 1.60 (1.32-1.95) <.0001
Local failure A1 664 176 19.6 (16.5-22.6) RL
A2 517 135 21.3 (17.7-24.8) 1.01 (0.81-1.27) .92
RTOG 9202 (n5 663)
Overall survival A1 352 178 88.1 (84.7-91.5) RL
A2 311 201 75.1 (70.3-79.9) 1.59 (1.30-1.94) <.0001
Distant metastasis A1 352 127 17.3 (13.4-21.3) RL
A2 311 139 29.3 (24.2-34.4) 1.42 (1.12-1.80) .004
Local failure A1 352 102 22.2 (17.8-26.5) RL
A2 311 90 25.1 (20.3-30.0) 1.03 (0.78-1.37) .086
RTOG 9413 (n5 518)
Overall survival A1 312 89 88.3 (84.6-91.9) RL
A2 206 98 73.8 (67.7-80.0) 1.97 (1.48-2.62) <.0001
Distant metastasis A1 312 66 13.7 (9.9-17.6) RL
A2 206 73 28.6 (22.4-34.9) 1.94 (1.39-2.70) <.0001
Local failure A1 312 74 16.6 (12.5-20.8) RL
A2 206 45 15.6 (10.5-20.7) 0.93 (0.64-1.35) .70
Abbreviations: ASTRO, American Society for Therapeutic Radiology and Oncology; CI, confidence interval; HR, hazard ratio; RL, reference level; RTOG, Radia-
tion Therapy Oncology Group.
a The cumulative incidence method was used to estimate distant and local failure rates, and Kaplan-Meier estimation was used for overall survival rates.
b An HR quantifies how much more (less) risk that patients at some level have in comparison with those at the RL. A CI that includes 1 indicates no difference
between these 2 subgroups.
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multivariate analyses, and this suggests that patients whose
failure is due only to a rising PSA level may be a distinctly
better performing group. Nevertheless, in the current analy-
sis, BF was defined on the basis of 3 consecutive rises (the
1997 ASTRO consensus definition), and this was similar to
the standard when the 2 phase 3 trials in question were initi-
ated and to how patients were frequently managed after
treatment. The more modern phoenix definition (PSA
nadir1 2 ng/mL) was not used clinically in these patients
and was not analyzed herein.2 However, because many
patients were started on ADT before they reached the phoe-
nix definition threshold (the median PSA level was 2.2 ng/
mL for those with rising PSA but not 3 rises; Table 2), the
current analysis, if performed with the phoenix definition,
would be more problematic in that more patients would be
classified as failing for causes other than a rise of 2 ng/mL.
Because the definition of 3 consecutive rises is
known to be more susceptible to PSA bounces or benign
rises in PSA after the cessation of ADT, that is one factor
that might underlie the more favorable outcomes for those
whose failure was determined by 3 consecutive rises.16
Nevertheless, if patients were diagnosed with BF on the
basis of 3 consecutive rises in the setting of false-positive
BF, it also seems likely that patients would also have high
false-positive rates if they had rising PSA levels but had
not reached 3 consecutive rises and were started on ADT
as part of the A2 group, and indeed this group (pattern 2;
Table 2) appeared to have very favorable clinical out-
comes, with a 90.3% 5-year survival rate and only a 7.9%
DM rate. Interestingly, for those with A1 BF who had a
rising PSA level after a nadir, the absolute nadir achieved
was not prognostic for outcomes, whereas the rate of the
PSA rise after a nadir was prognostic. Some have sug-
gested that that the absolute PSA nadir after RT and ADT
is prognostic for those treated with short-term
ADT13,14,17; however, it is possible that for those treated
with long-term ADT, the influence of the absolute PSA
nadir is smaller.18 Furthermore, in those with an A1 fail-
ure, the time to achieve a nadir was also prognostic, with a
longer time to a nadir being more favorable; however, this
variable is susceptible to an immortality bias because fail-
ure cannot be called until a nadir has been reached, and
TABLE 4. Multivariate Models for Overall Survival, Distant Metastasis, Local Failure, and Salvage ADT Use
for Patients Treated in RTOG 9202 or RTOG 9413
Endpoint Covariate Comparison HR (95% CI) P
Overall survivala BF type A1 RL
A2 1.66 (1.40-1.97) <.0001
Age, y <70 RL
70 1.43 (1.20-1.69) <.0001
Gleason score 2-6 RL
7-10 1.54 (1.26-1.89) <.0001
Distant metastasisa BF type A1 RL
A2 1.60 (1.31-1.95) <.0001
Gleason score 2-6 RL
7-10 1.53 (1.18-1.97) .0012
Stage T2 RL
>T2 1.70 (1.31-2.20) <.0001
Study 9202 RL
9413 0.68 (0.54-0.85) .0007
Local failurea BF type A1 RL
A2 0.97 (0.77-1.22) .78
Stage T2 RL
>T2 1.54 (1.18-2.02) .0016
Study 9202 RL
9413 0.69 (0.54-0.88) .0024
Time to salvage ADT after BF (A1 failure only) Age, y <70 RL
70 0.91 (0.75-1.10) .34
Gleason score 2-6 RL
7-10 1.12 (0.90. 1.39) .32
Stage T2 RL
>T2 1.07 (0.87-1.31) .54
Study 9202 RL
9413 1.40 (1.15-1.70) <.001
Abbreviations: ADT, androgen-deprivation therapy; BF, biochemical failure; CI, confidence interval; HR, hazard ratio; RL, reference level; RTOG, Radiation Ther-
apy Oncology Group.
a All the outcomes of the combined data in the multivariate proportional hazards models were adjusted by BF type (A1 [RL]), age (<70 [RL] vs 70 years),
combined Gleason score (2-6 [RL] vs 7-10), PSA (30 [RL] vs >30 ng/mL), clinical classification (T2 [RL] vs >T2), and study (RTOG 9202 [RL] vs RTOG
9413).
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this artificially biases results without adjustments such as
landmark or time-dependent analyses.17
This analysis also suffers from the fact that the A2
group was rather heterogeneous (Table 2). The reasons
that a patient could be classified as A2 included a continu-
ally rising PSA level after treatment, a rise in PSA (that did
not meet the definition of 3 rises), the appearance of
symptomatic metastasis, local progression on clinical ex-
amination, and the initiation of salvage ADT for an
unspecified reason. Although this group was heterogene-
ous, in the multivariate analysis, which included signifi-
cant covariates for treatment failure (age, PSA, T
classification, Gleason score, and ADT duration), it was
still found that the patients with A2 failure had worse OS
and DM rates than those with 3 consecutive rises. Overall,
this lends credence to the adverse impact of A2 failure de-
spite its heterogeneous nature and the better outcomes for
those with rising PSA alone.
Patients from this analysis were treated exclusively
with external-beam RT, and the results may not be
directly applicable to patients treated with either prostate
brachytherapy or prostatectomy. The use of PSA for the
determination of BF after brachytherapy, however,
appears to correlate, as with external-beam therapy, with
ultimate clinical failure,19 so one might expect that non–
PSA-rising brachytherapy failures may act similarly to
non–PSA-rising external-beam failures.20 In addition,
because the prognostic benefit of A2 failure appears
primarily for distant recurrences, the local treatment mo-
dality may not be significant. Although this study did
identify similar local failure rates in the A1 and A2 failure
groups, the evaluation of local failure was limited because
rebiopsy was not required or performed in the vast ma-
jority of these patients. Nevertheless, one would assume
that this lack of evaluation would have been relatively
equally distributed throughout the entire study popula-
tion; therefore, although local failure rates may be under-
estimated, the relative impact of local failure should not
be different on the basis of the definition of BF.
The PSA pattern most commonly seen after A2 fail-
ure was one of PSA decreasing to a nadir after treatment
and then rising (approximately 55% of all A2 patients; Ta-
ble 2). In this group, the median PSA doubling time was
22.6 months (mean, 98.9 months). Because of the wide
range of PSA doubling times (3.0-2718 months), it
appears that the PSA doubling time is not useful in the A2
population in contrast to A1 patients, as seen in other stud-
ies.21,22 The median PSA nadir for this group was 0.2 ng/
mL (mean, 0.43 ng/mL), and although others have dem-
onstrated that patients with a PSA nadir less than 0.8 or
0.2 ng/mL may have a good prognosis,13,14,17,18 this does
not seem to be the case for A2 failures, for which a PSA na-
dir was not prognostic. Additional work regarding prog-
nostic factors in the A2 population is warranted, although
it appears that patients with DM as the first failure (pattern
4) and patients with a rising PSA level after RT without a
nadir (pattern 1) were the 2 groups with the greatest risk of
overall mortality, and they accounted for 33.2% of all A2
failures. In a previous analysis of RTOG 8610, those who
started salvage ADT after the development of DM had
substantially worse survival than those who started salvage
ADT without metastasis (median OS after salvage ADT:
4.9 vs 2.8 years).23 In comparison, for those without me-
tastasis at the time of the initiation of salvage ADT, the dif-
ference in median survival as a function of PSA was much
smaller: 5.3 years for those with a PSA level< 20 ng/mL at
the time of salvage ADT and 4.3 years for those for whom
salvage ADT was started with a PSA level of 20 ng/mL or
higher. Nevertheless, differences in unmeasured confound-
ers between these groups (eg, PSA kinetics at the time of
salvage ADT) may account for the observed differences in
outcomes and may not necessarily support an improved
outcome with early salvage ADT for those with only bio-
chemical recurrence of prostate cancer. In addition to me-
tastasis, which could have influenced A2 failures and led to
worse clinical outcomes, early BF (with a short interval to
BF) has also been identified as carrying a significantly
increased risk of death from prostate cancer24,25 or death
TABLE 5. Multivariate Proportional Hazards Models
for RTOG 9202 and RTOG 9413: Time to Biochemi-
cal Failure for Those Meeting the A1 Definition of
Biochemical Failure
Covariate Comparison Adjusted HR (95% CI)a P
PSA nadir Continuous 0.93 (0.81-1.1) .34
Study 9202 RL
9413 1.54 (1.32-1.79) <.0001
Time to PSA nadir Continuous 0.99 (0.99-0.995) <.0001
Study 9202 RL
9413 1.43 (1.24-1.66) <.0001
Rate of PSA riseb Continuous 1.19 (1.12-1.27) <.0001
Study 9202 RL
9413 1.55 (1.33-1.80) <.0001
Abbreviations: CI, confidence interval; HR, hazard ratio; PSA, prostate-
specific antigen; RL, reference level; RTOG, Radiation Therapy Oncology
Group.
a An HR quantifies how much more (less) risk that patients at some level
have in comparison with those at the RL. A CI that includes 1 indicates no
difference between these 2 subgroups. All the outcomes of the combined
data in the multivariate proportional hazards models were adjusted by age
(<70 [RL] vs 70 years), combined Gleason score (2-6 [RL] vs 7-10), PSA
(30 [RL] vs >30 ng/mL), clinical classification (T2 [RL] vs >T2), and
study (RTOG 9202 [RL] vs RTOG 9413).
b Rate of PSA rise5 (PSA at failure2PSA at nadir)/(Date of PSA failur-
e2Date of PSA nadir).
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overall.26 and it may have been captured in the A2 defini-
tion, particularly for those men who had continually rising
PSA after RT or recurrence even during ADT.
In conclusion, patients deemed to have A2 BF may
have biologically more aggressive disease with worse OS
and DM rates, and this warrants additional study. As a
result, those with A1 failure by virtue of rising PSA alone
may carry less clinical risk. Further investigation of this
phenomenon in other clinical trials and with the current
definition of BF is warranted.
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